AngioDynamics Receives EU CE Mark Approval for AngioVac

AngioDynamics ANGO today announced EU CE Mark approval for its AngioVac venous drainage cannula and cardiopulmonary bypass circuit for use during extracorporeal bypass for up to six hours. Under the CE Mark approval the AngioVac cannula is also approved for removal of fresh, soft thrombi or emboli. "The AngioVac cannula and circuit have shown great promise in improving patient outcomes and reducing the cost of treatment when dealing with the removal of soft thrombus," said John Soto, Senior Vice President of AngioDynamics' Global Peripheral Vascular Franchise. "CE Mark approval makes this powerful tool available to physicians across the EU." The AngioVac cannula and circuit, when combined with other manufacturers' filters, pumps and return cannula, comprise an extracorporeal bypass circuit that facilitates drainage, filtration and reinfusion of blood for up to six hours. The AngioVac Cannula has a proprietary balloon-actuated, expandable, funnel-shaped distal tip to enhance flow, prevent clogging of the cannula and facilitate en bloc removal of undesirable intravascular material. Venous thromboembolic events are a leading cause of morbidity and mortality, and the annual number of See full press release